SPRBSpruce Biosciences, Inc.
The schedule
- Thu15Oct
A potential secondary equity offering to extend the cash runway ahead of pivotal work could be received as prudent financing if sized and priced well, allowing the stock to stabilize or modestly improve from $51.69 toward $55.00, but there is significant risk of a sharp selloff toward $55.00 if investors view the raise as overly dilutive or poorly timed.
- Sat5Dec
Top-line Phase 2b efficacy and safety data for tildacerfont in CAH is the pivotal binary catalyst, with strong results capable of propelling the stock from $51.69 toward $95.00, while a miss on efficacy, safety, or tolerability could drive a severe de-rating toward $95.00.
- Wed23Dec
An endocrinology conference update on CAH and related endocrine programs, including trial design and regulatory feedback, could move the stock from $51.69 toward $72.00 if the path to registration looks clean, or down toward $72.00 if study design, endpoints, or timelines raise new concerns.
- Wed10Mar
FY 2026 results and 2027 development guidance will update the market on post–Phase 2b strategy, cash runway, and potential partnering, with constructive guidance and adequate liquidity supporting a move from $51.69 toward $60.00, while weaker balance sheet visibility or a lack of strategic options could pull the stock toward $60.00.
- Mon17May
- Wed18Aug
Past
- Fri14Aug
Actual outcome: Mixed
Spruce Biosciences reported Q2 2026 EPS of -$10.67, exactly in line with consensus estimates, alongside a $5.5 million strategic investment from the Cure Sanfilippo Foundation and National MPS Society. The stock remained flat following the update, as the in-line financial results and foundation funding provided stability but lacked the significant pipeline catalysts needed to drive a directional breakout.
Q2 2026 earnings will refocus investors on R&D execution and any refinements to the tildacerfont pipeline, with a constructive update capable of driving the stock from $51.69 toward $70.00, while weaker visibility or higher burn could push it down toward $70.00.
- Wed13May
Actual outcome: Bear · $51.89 at outcome
Spruce Biosciences reported Q1 EPS of -$10.67, exactly meeting consensus estimates. Despite meeting bottom-line expectations, the stock fell 9.8% over the following month as management's updates regarding cash runway and the tildacerfont program failed to provide the necessary visibility. Concerns over cash burn and development timelines ultimately weighed on investor sentiment, driving the downward price action.
Q1 2026 results and management's updated cash runway commentary around the tildacerfont program will be key for sentiment, with the stock at $51.69 and a potential move toward $65.00 if burn is well controlled and trial timelines are reaffirmed, or down toward $65.00 if cash visibility or development plans disappoint.
- Mon20Apr
Actual outcome: Bear · $51.27 at outcome
Spruce Biosciences announced the pricing of an underwritten public offering of 1,150,000 shares of its common stock and pre-funded warrants. The dilutive capital raise and the pricing terms of the offering led to a sharp decline in the stock price as investors digested the equity dilution. [Market retrospective · Ultra-Short (1–5 days)] Missed anticipation: -26.1% from 2026-04-20 to 2026-05-29 (~1.4σ vs typical 1d vol). Target date 2026-04-23 reached; move through 2026-05-29 observed. Confidence 95%.
Spruce Biosciences announced the pricing of an underwritten public offering of 1,150,000 shares of its common stock and pre-funded warrants. The dilutive capital raise and the pricing terms of the offering led to a sharp decline in the stock price as investors digested the equity dilution. [Market retrospective · Ultra-Short (1–5 days)] Missed anticipation: -26.1% from 2026-04-20 to 2026-05-29 (~1.4σ vs typical 1d vol). Target date 2026-04-23 reached; move through 2026-05-29 observed. Confidence 95%.